Familial hemophagocytic lymphohistiocytosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:540OMIM:267700D76.1
Who is this for?
Show terms as
9Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Familial hemophagocytic lymphohistiocytosis (FHL), also known as familial erythrophagocytic lymphohistiocytosis or primary hemophagocytic lymphohistiocytosis, is a rare and life-threatening inherited disorder of the immune system. It belongs to a group of conditions called hemophagocytic lymphohistiocytosis (HLH), characterized by uncontrolled activation and proliferation of T lymphocytes and macrophages that infiltrate multiple organs. This excessive immune activation leads to widespread tissue damage and organ dysfunction. The disease primarily affects the hematologic, hepatic, neurological, and immune systems. Key clinical features include prolonged high fever, enlarged liver and spleen (hepatosplenomegaly), cytopenias (low blood cell counts affecting red blood cells, white blood cells, and platelets), elevated ferritin and triglycerides, low fibrinogen, and evidence of hemophagocytosis (macrophages engulfing blood cells) in the bone marrow, spleen, or lymph nodes. Neurological involvement is common and may include irritability, seizures, cranial nerve palsies, ataxia, and altered consciousness. Liver dysfunction with jaundice and coagulopathy may also occur. Without treatment, the disease is rapidly fatal. Several genetic subtypes have been identified: FHL type 2 (PRF1 gene), FHL type 3 (UNC13D gene), FHL type 4 (STX11 gene), and FHL type 5 (STXBP2 gene). These genes encode proteins essential for the cytotoxic function of natural killer cells and cytotoxic T lymphocytes. Treatment involves immunosuppressive and chemotherapeutic protocols, most commonly the HLH-94 or HLH-2004 protocols, which include dexamethasone, etoposide, and cyclosporine A. Intrathecal methotrexate may be used for central nervous system involvement. However, the only curative treatment is allogeneic hematopoietic stem cell transplantation (HSCT), which is recommended for all patients with confirmed familial forms of the disease.

Also known as:

Clinical phenotype terms— hover any for plain English:

Abnormal natural killer cell physiologyHP:0012177Immune dysregulationHP:0002958Abnormal circulating cytokine concentrationHP:0011112Abnormality of tumor necrosis factor secretionHP:0011118Abnormality of multiple cell lineages in the bone marrowHP:0012145HemophagocytosisHP:0012156Increased circulating interferon-gamma concentrationHP:0030356
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Familial hemophagocytic lymphohistiocytosis.

View clinical trials →

No actively recruiting trials found for Familial hemophagocytic lymphohistiocytosis at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Familial hemophagocytic lymphohistiocytosis community →

Specialists

9 foundView all specialists →
NM
Nirali N Shah, M.D.
Specialist
PI on 7 active trials
RM
Robert A. Krance, MD
VERONA, PA
Specialist
PI on 1 active trial
AM
Anna Scherbina, MD,Phd
MATAWAN, NJ
Specialist
PI on 1 active trial
RP
Rui Zhang, MD, Prof
Specialist
PI on 1 active trial
LS
Laurent Servais
Specialist
PI on 1 active trial28 Familial hemophagocytic lymphohistiocytosis publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Familial hemophagocytic lymphohistiocytosis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Familial hemophagocytic lymphohistiocytosisForum →

No community posts yet. Be the first to share your experience with Familial hemophagocytic lymphohistiocytosis.

Start the conversation →

Latest news about Familial hemophagocytic lymphohistiocytosis

1 articles
NewsJ GASTROINTESTIN LIVER DISMar 27, 2026
A Rare Case Report of Primary Hepatic Lymphoma Complicated by Hemophagocytic Lymphohistiocytosis
Published in J Gastrointestin Liver Dis. Zhang Y et al.
See all news about Familial hemophagocytic lymphohistiocytosis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Familial hemophagocytic lymphohistiocytosis

What is Familial hemophagocytic lymphohistiocytosis?

Familial hemophagocytic lymphohistiocytosis (FHL), also known as familial erythrophagocytic lymphohistiocytosis or primary hemophagocytic lymphohistiocytosis, is a rare and life-threatening inherited disorder of the immune system. It belongs to a group of conditions called hemophagocytic lymphohistiocytosis (HLH), characterized by uncontrolled activation and proliferation of T lymphocytes and macrophages that infiltrate multiple organs. This excessive immune activation leads to widespread tissue damage and organ dysfunction. The disease primarily affects the hematologic, hepatic, neurological,

How is Familial hemophagocytic lymphohistiocytosis inherited?

Familial hemophagocytic lymphohistiocytosis follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Familial hemophagocytic lymphohistiocytosis typically begin?

Typical onset of Familial hemophagocytic lymphohistiocytosis is infantile. Age of onset can vary across affected individuals.

Which specialists treat Familial hemophagocytic lymphohistiocytosis?

9 specialists and care centers treating Familial hemophagocytic lymphohistiocytosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.